ERBB2 and colorectal carcinoma: Given the presence of RAS mutations in CRC, some researchers advocate for the use of next-generation sequencing (NGS) to detect HER2 amplifications and, thus, refine the selection of metastatic CRC patients, who may be candidates for anti-EGFR therapy [11,13,47,53,54].